VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - Feb. 19, 2007) - Pyng Medical Corp. (TSX VENTURE:PYT) is pursuing Chinese FDA (SFDA) regulatory registration in support of launching the FAST1(TM) Intraosseous Infusion System into The People's Republic of China. Pyng has retained Beijing Jyton & Kannel Medical Technology Co., Ltd. as its exclusive regulatory representative in China.
"The opportunity for FAST1(TM) in China is as enormous as the country itself. With advancements in Chinese health care, the world's largest standing military, and a vast network of emergency medical service needs, Pyng is perfectly positioned to penetrate this huge and growing market with our innovative FAST1(TM) Intraosseous Infusion System," said David Christie, President and Chief Executive Officer of Pyng.
Beijing Jyton & Kannel is an experienced Chinese company with a track record of successfully registering medical devices for its overseas clients. They will be working closely with Pyng and Pyng's Asian representative, Business Asia Consultants.
About Pyng Medical Corp.
www.pyng.com
Pyng Medical Corp. is a world leader in intraosseous infusion with its proprietary award-winning FAST1(TM) Intraosseous Infusion System, the only device able to provide rapid sternal access and delivery of life saving fluids and drugs to the heart of critically injured patients within seconds. The FAST1(TM) is used extensively by the U.S. Department of Defense and by Emergency Medical Services around the globe.
Safe Harbour Statement; Forward-Looking Statements: This release may contain forward-looking statements based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects", "anticipates", "plans", "intends", "projects", "indicates", and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents which may be filed with the British Columbia Securities Commission, the Alberta Securities Commission, the Ontario Securities Commission, the TSX Venture Exchange, as well as other USA Commissions, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the Company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw material, research and development of new products, including regulatory approval and market acceptance; and seasonality of sales in some products.
FOR FURTHER INFORMATION PLEASE CONTACT:
Pyng Medical Corp.
David Christie
(604) 303-7964
Website: www.pyng.com
